Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

HYDROMORPHONE HCL

All products: general benefit

Other products in the same Health Canada class (N02A, N02AA) — coverage varies; not interchangeable

  • Morphine (M-Eslon): general benefit, Not a benefit
  • Acetylsalicylic acid + butalbital + caffeine + codeine (Fiorinal C1/4): not a benefit
  • Oxycodone (Supeudol): not a benefit
  • Acetaminophen + caffeine + codeine (Teva-Lenoltec No.2): general benefit, Not a benefit
  • Acetaminophen + codeine (PMS-Acetaminophen With Codeine): general benefit, Not a benefit
  • Acetaminophen + oxycodone (Teva-Oxycocet): general benefit, Not a benefit

4 more in the class list below

Hydromorph Contin · DIN 02125366 · 12mg · CR capsule

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Hydromorph Contin · DIN 02125366 Manufacturer: Purdue Pharma; listing date 1998-12-31 Health Canada: Marketed since 1996-12-31 · brand HYDROMORPH CONTIN-CONTROLLED RELEASE CAP - 12MG · ATC N02AA03 HYDROMORPHONE · form Capsule (sustained-release) · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 12 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Hydromorph Contin: Formulary list price $2.0990/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.0990 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20171 · Verify on the e-Formulary ↗ (DIN 02125366)

Source record
DIN 02125366: Hydromorph Contin Raw flags: sec3=Y Item: 280808099; group id 406; item number 0971; lccId None; manufacturer id PFP Source form: CR Cap; strength: 12mg Recorded listing: General benefit Source prices (unrounded): $2.0990; ministry $2.0990 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02125366 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20171
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (28:08:08 Opiate Agonists) and how they are covered

Matched class: 28:08:08 Opiate Agonists

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE, ACETAMINOPHEN & CODEINE PHOSPHATE, CODEINE PHOSPHATE, METHADONE HCL, MORPHINE SULFATE, OXYCODONE HCL & ACETAMINOPHEN, OXYCODONE HCL & ACETYLSALICYLIC ACID 28:08:08 Opiate Agonists

MORPHINE SULFATE

· 35 products · General benefit (31), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 10mg, 15mg, 30mg, 60mg, 100mg, 2mg/mL, 10mg/mL, 15mg/mL, 50mg/mL, 20mg, 50mg, 200mg, 5mg · ER Cap, Inj Sol Amp, Inj Sol-1mL Pk, SR Cap, SR Tab, Tab

ACETYLSALICYLIC ACID & BUTALBITAL & CAFFEINE & CODEINE PHOSPHATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 330mg & 50mg & 40mg & 15mg, 330mg & 50mg & 40mg & 30mg · Cap

OXYCODONE HCL

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg, 20mg · Tab

ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 300mg & 15mg & 15mg, 300mg & 15mg & 30mg · Tab

ACETAMINOPHEN & CODEINE PHOSPHATE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 160mg & 8mg/5mL, 300mg & 30mg, 300mg & 60mg · O/L, Tab

OXYCODONE HCL & ACETAMINOPHEN

· 5 products · General benefit (4), Listed, not a benefit (1) · strengths: 5mg & 325mg · Tab

OXYCODONE HCL & ACETYLSALICYLIC ACID

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 5mg & 325mg · Tab

FENTANYL TRANSDERMAL SYSTEM

· 22 products · Listed, not a benefit (6), Limited Use, codes 511 (6), Limited Use, codes 689 (2), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 12mcg/hr, 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr · Trans Patch

TRAMADOL HCL

· 13 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 200mg, 300mg, 50mg · ER Tab, Tab

TRAMADOL HCL & ACETAMINOPHEN

· 11 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 37.5mg & 325mg · Tab

CODEINE PHOSPHATE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 15mg, 30mg · Tab

METHADONE HCL

· 16 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg/mL, 1mg, 5mg, 10mg, 25mg · Oral Concentrate, Oral Concentrate (Cherry Flavour), Oral Concentrate (Unflavoured), Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:08:08 and 2 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: pain
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE · General benefit (2), Listed, not a benefit (2) INDICATIONS AND CLINICAL USE Adults TEVA-LENOLTEC No. 2 and No. 3 (acetaminophen, caffeine and codeine phosphate) are indicated for the short-term relief of mild to moderate pain. PM: https://pdf.hres.ca/dpd_pm/00065848.PDF; date July 15, 2014; DIN 00653241; fetched 2026-09-10 Product monograph BUTORPHANOL TARTRATE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS Adults BUTORPHANOL Nasal Spray (butorphanol tartrate) is indicated for: • the relief of moderate to severe acute pain. PM: https://pdf.hres.ca/dpd_pm/00069311.PDF; date MAR 24, 2015; DIN 02242504; fetched 2026-09-10 Product monograph CELECOXIB · Limited Use, codes 316, 317 1 INDICATIONS CELEBREX (celecoxib capsules) is indicated for relief of symptoms associated with: • Osteoarthritis, • Adult Rheumatoid Arthritis, and • Ankylosing Spondylitis CELEBREX is also indicated for the short-term ( 7 days) management of moderate to severe acute pain in adults in conditions such as the following: • Musculoskeletal and/or soft tissue trauma including sprains, • Postoperative orthopaedic, and • Pain following dental extraction CELEBREX, particularly at doses higher than 200 mg per day, is associated with an increased risk of serious cardiovascular related adverse events (such as myocardial infarction, stroke or thrombotic events), which can be fatal. PM: https://pdf.hres.ca/dpd_pm/00080998.PDF; date 2025-07-09; DIN 02239941; fetched 2026-09-10 Product monograph CODEINE SULFATE TRIHYDRATE & MONOHYDRATE · Limited Use, codes 201 1 Indications CODEINE CONTIN (codeine controlled release tablets) is indicated for the relief of mild to moderate pain in adults requiring the prolonged use of an opioid analgesic preparation. PM: https://pdf.hres.ca/dpd_pm/00078791.PDF; date 2025-03-04; DIN 02163748; fetched 2026-09-10 Product monograph OXYCODONE HCL · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS Supeudol® 5 (oxycodone hydrochloride tablets) / Supeudol® 10 (oxycodone hydrochloride tablets) is indicated for: • relief of moderate to severe pain. PM: https://pdf.hres.ca/dpd_pm/00080231.PDF; date not captured; DIN 00443948; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS DILAUDID® (HYDROmorphone hydrochloride) is indicated for the relief of moderate to severe pain in adults. 1.1 Pediatrics No data are available to Health Canada. Therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, and titrated slowly, reflecting the greater frequency of decreased hepatic, renal or cardiac function, concomitant disease or other drug therapy (see 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00072218.PDF PM date: August 29, 2023 Source product: DILAUDID; DIN 00125083; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.